JPMorgan Chase restated their overweight rating on shares of Vectura Group (LON:VEC) in a report released on Thursday, March 22nd. They currently have a GBX 140 ($2.00) price target on the stock.
VEC has been the topic of several other reports. Peel Hunt reiterated a hold rating and issued a GBX 120 ($1.72) price objective on shares of Vectura Group in a research note on Wednesday, March 21st. Shore Capital reissued a buy rating on shares of Vectura Group in a report on Thursday, January 4th. Numis Securities reissued a buy rating and issued a GBX 170 ($2.43) target price on shares of Vectura Group in a report on Thursday, January 4th. Citigroup reissued a buy rating and issued a GBX 155 ($2.22) target price on shares of Vectura Group in a report on Tuesday, March 20th. Finally, Royal Bank of Canada raised Vectura Group to a sector performer rating and set a GBX 119 ($1.70) target price on the stock in a report on Thursday, December 14th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Vectura Group presently has a consensus rating of Buy and a consensus price target of GBX 139.38 ($2.00).
Shares of VEC stock traded down GBX 7.50 ($0.11) during trading hours on Thursday, reaching GBX 97 ($1.39). The company had a trading volume of 11,244,078 shares, compared to its average volume of 4,610,000. Vectura Group has a 12-month low of GBX 70 ($1.00) and a 12-month high of GBX 166.97 ($2.39).
COPYRIGHT VIOLATION NOTICE: This report was posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://macondaily.com/2018/04/17/vectura-groups-vec-overweight-rating-reiterated-at-jpmorgan-chase-co-updated-updated-updated.html.
Vectura Group Company Profile
Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company's marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; and Adept for the treatment of surgical adhesions.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.